GlassScriptPhysician profile
Anuradha Reddy
NPI 1760559009
$20,129.54
in general payments reported to CMS, 2019-2025
44 companies · $3,487 in 2025
The $3,487 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,931 · 2020: $1,544 · 2021: $1,856 · 2022: $2,784 · 2023: $2,535 · 2024: $1,992 · 2025: $3,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,667 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,320 · Education: $26.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,666.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,320.00 |
| Education | $26.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $3,741.58 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $2,848.85 | 2019-2023 | Krystexxa |
| Pfizer INC. | $1,390.96 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,260.71 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $991.35 | 2019-2025 | |
| Glaxosmithkline, LLC. | $959.25 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $860.31 | 2019-2023 | Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $779.16 | 2022-2025 | |
| Lilly USA, LLC | $726.06 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $720.53 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Astellas Pharma US INC | $556.73 | 2019-2021 | |
| Novo Nordisk INC | $545.80 | 2019-2025 | Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $518.48 | 2023-2025 | Gemtesa, Myfembree |
| Janssen Biotech, INC. | $465.94 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $461.56 | 2019-2024 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuradha Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.